Skip to content

Author

Cédric Hermans

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors.

BACKGROUND Denecimig (Mim8) is an activated factor VIII mimetic, fully human, bispecific IgG4 antibody in development for subcutaneous prophylaxis in patients with haemophilia A (HA) with/without inhibitors. OBJECTIVE To evaluate the safety and patient experience of a direct switch from emicizumab to denecimig prophy...

Cédric Hermans, Gary Benson, D. Matino et al. · 1 citation
Open access Oct 2026

Clinical efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII in long-term prophylaxis study in patients older than 6 years with severe von Willebrand disease

Benefits of long-term prophylaxis (LTP) in patients with severe von Willebrand disease (VWD) were well established by several studies. However, data on treatment modalities to gain optimal dosing and infusion schedule are limited. To assess the efficacy and safety of LTP with a plasma-derived von Willebrand...

Cédric Hermans, B. Meddeb, Q. Van Thillo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.